This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has increasing prostate-specific antigen after treatment (biochemically recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Typically drug-related cancer care is conducted at a medical center which causes patients to have to spend considerable time away from family, friends, and familiar surroundings. This separation may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. Therapy administered to a patient in the patients' residence in the comfort of familiar surrounding using Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) may help reduce psychological and financial distress, increase access to care and improve treatment compliance. Giving cancer therapy in the home compared in the clinic may be safe, tolerable and improve patient satisfaction with overall cancer care in Black men with locally advanced, biochemically recurrent or metastatic prostate cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Patient rating of overall cancer care experience - CAHPS
Timeframe: Up to 48 weeks
Patient preferences regarding the location of cancer treatment delivery
Timeframe: Up to 48 weeks
Incidence of grade 3+ adverse events (AEs)
Timeframe: Up to 30 days after last dose of study treatment
Acute care visits, emergency room visits, and hospitalizations
Timeframe: Up to 48 weeks
Avoidable acute care visits, emergency room visits and hospitalizations
Timeframe: Up to 48 weeks